Format

Send to

Choose Destination
Lancet Oncol. 2016 Nov;17(11):e468. doi: 10.1016/S1470-2045(16)30499-5.

Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer.

Author information

1
Department of Medical Oncology, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris 75014, France. Electronic address: olivier.huillard@aphp.fr.
2
Department of Nuclear Medicine, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris 75014, France.
3
Department of Medical Oncology, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris 75014, France.
4
Department of Endocrinology, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris 75014, France.
PMID:
27819235
DOI:
10.1016/S1470-2045(16)30499-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center